Four programs, one platform

Product Pipeline

Our programs share one architecture on RNA level and differ only in two modules: the marker that switches the construct on, and the effector it expresses. That is why a cancer program and a fibrosis program can run on the same platform. All programs are in preclinical development.

Target Discovery
In vitro/in vivo PoC
IND-enabling studies
IND
Mode of Action
Oncology
Hepatocellular Carcinoma
Cell killing
Lung cancer
Cell killing
Non-Oncology
Liver Fibrosis
Cell re-programming
Autoimmune Diseases
Activity dampening

Interested in partnering?

We are open to partnerships on selected programs and the platform.